Streetbeat News

Price Targets

TSLA

Deutsche Bank analyst Emmanuel Rosner has maintained a Buy rating on Tesla (NASDAQ:TSLA) but reduced the price target from $275 to $260.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:49 pm

CBT

UBS analyst Joshua Spector has reaffirmed a Buy rating on Cabot Corporation (NYSE:CBT) and increased the price target from $83 to $90.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:49 pm

MRO

UBS analyst Josh Silverstein downgraded Marathon Oil (MRO) from Buy to Neutral and reduced the price target from $34 to $28, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:47 pm

CHK

UBS analyst Josh Silverstein downgraded Chesapeake Energy (NASDAQ:CHK) from Buy to Neutral and reduced the price target from $106 to $86, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:46 pm

OC

Owens Corning (OC) shares are up as JP Morgan and Goldman Sachs maintain Neutral ratings but increase their price targets to $161 and $147, respectively.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:46 pm

CTRA

UBS analyst Josh Silverstein has upgraded Coterra Energy (NYSE:CTRA) from Neutral to Buy, while also reducing the price target from $33 to $31.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:42 pm

ZG

RBC Capital analyst Brad Erickson has reiterated an Outperform rating on Zillow Group (NASDAQ:ZG) and maintained a price target of $56.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:40 pm

PHM

PluteGroup's stock (PHM) is trading higher following Goldman Sachs' decision to maintain a Neutral rating while increasing the price target from $80 to $91.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:39 pm

VRDN

RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:39 pm

VRTX

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and increased the price target from $347 to $379.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 3:37 pm